Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Forest/Mylan Respond To FDA “Approvable” Letter On Nebivolol

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Forest estimates review of the novel hypertension drug could take six months.

You may also be interested in...



Bystolic Approved; Forest Prepares To Launch In Crowded Beta Blocker Market

Firm hopes nebivolol's subgroup efficacy will set the novel beta blocker apart from others in its class.

Bystolic Approved; Forest Prepares To Launch In Crowded Beta Blocker Market

Firm hopes nebivolol's subgroup efficacy will set the novel beta blocker apart from others in its class.

Forest And Mylan Confident Nebivolol Will Reach Market In Early 2008

FDA “approvable” letter seen by firms as minor hurdle for previously delayed hypertension drug.

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

Finding The Sweet Spot For Real-World Evidence: Aetion Stresses Early Feasibility Assessment

FDA Gene Therapy Office Chief Prefers Flexibility With Accelerated Approval Confirmatory Trials

Keeping Track: Return & Renewal At US FDA

Korean Bioclusters Offer Tax, Other Incentives To Attract Global Firms, Talent

See All
UsernamePublicRestriction

Register

PS066009

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By